Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  BeiGene, Ltd.    BGNE

BEIGENE, LTD.

(BGNE)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
03/01/2021 03/02/2021 03/03/2021 03/04/2021 03/05/2021 Date
319.39(c) 306.46(c) 304.55(c) 289.22(c) 301.28(c) Last
369 175 215 014 187 635 304 625 428 427 Volume
-0.19% -4.05% -0.62% -5.03% +4.17% Change
More quotes
Financials (USD)
Sales 2021 898 M - -
Net income 2021 -1 324 M - -
Net cash position 2021 2 405 M - -
P/E ratio 2021 -22,4x
Yield 2021 -
Sales 2022 1 505 M - -
Net income 2022 -633 M - -
Net cash position 2022 1 728 M - -
P/E ratio 2022 -38,0x
Yield 2022 -
Capitalization 27 598 M 27 598 M -
EV / Sales 2021 28,0x
EV / Sales 2022 17,2x
Nbr of Employees 5 300
Free-Float 69,0%
More Financials
Company
BeiGene, Ltd. is principally engaged in biopharmaceutical business. The Company is mainly engaged in the research and development, production and sales of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company's main products include Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317) and Pamiparib (BGB-290). 
More about the company
Notations Surperformance© of BeiGene, Ltd.
Trading Rating : Investor Rating :
More Ratings
All news about BEIGENE, LTD.
03/05BEIGENEá : Supplemental Biologics License Application Accepted in China for Non-..
MT
03/05BEIGENE, LTD.á : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
03/05BEIGENEá : Says China Regulator Accepts sBLA for Teslelizumab in Second- or Thir..
MT
03/05BEIGENEá : Announces Acceptance of a Supplemental Biologics License Application ..
BU
03/03BEIGENEá : Health Canada Approves BRUKINSA for the Treatment of Waldenstrom's Ma..
AQ
03/02BEIGENEá : Blood Cancer Drug Brukinsa Wins Regulatory Nod in Canada
MT
03/02BEIGENEá : Voluntary announcement - update regarding recent business development..
PU
03/02BEIGENE, LTD.á : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
03/02BEIGENEá : Brukinsa Approved by Health Canada to Treat Waldenstrom's Macroglobul..
MT
03/02BEIGENEá : Health Canada Approves BRUKINSA« (Zanubrutinib) for the Treatment of ..
BU
03/01BEIGENEá : Grant of share options
PU
03/01BEIGENEá : CLSA Downgrades BeiGene to Underperform From Outperform, Adjusts Pric..
MT
03/01BEIGENEá : Announces Closing of Collaboration with Novartis to Develop and Comme..
AQ
03/01BEIGENEá : Novartis strengthens Oncology pipeline with successful closing of tis..
AQ
03/01BeiGene Closes $650 Million Drug Licensing Deal with Novartis
MT
More news
News in other languages on BEIGENE, LTD.
02/26NOVARTISá : finalisation de l'accord avec BeiGene
02/26NOVARTISá : will Krebsmedikament gemeinsam mit Chinas Beigene entwickeln
02/26Novartis schliesst Einlizenzierung von Tislelizumab ab
01/12MÄRKTE USA/Wall Street nach Vortagesverlusten behauptet
01/12MÄRKTE USA/US-Börsen knapp behauptet
More news
Analyst Recommendations on BEIGENE, LTD.
More recommendations
Chart BEIGENE, LTD.
Duration : Period :
BeiGene, Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BEIGENE, LTD.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 331,92 $
Last Close Price 301,28 $
Spread / Highest target 42,4%
Spread / Average Target 10,2%
Spread / Lowest Target -47,6%
EPS Revisions
Managers and Directors
NameTitle
John V. Oyler Chairman & Chief Executive Officer
Xiao Bin Wu President & General Manager-China Region
Howard Liang Chief Financial & Strategy Officer
Jane E. Huang Chief Medical Officer-Hematology
Yong Ben Chief Medical Officer-Immuno & Oncology Department
Sector and Competitors
1st jan.Capitalization (M$)
BEIGENE, LTD.11.93%27 598
GILEAD SCIENCES, INC.7.71%81 201
VERTEX PHARMACEUTICALS-12.08%55 106
WUXI APPTEC CO., LTD.0.64%50 791
REGENERON PHARMACEUTICALS-7.53%48 070
BIONTECH SE16.72%23 164